Rhythm Pharmaceuticals, Inc. (RYTM)

Rhythm Pharmaceuticals' stock (RYTM) closed at $103.87 on February 5, 2026, with a 52-week high of $122.20 and a low of $45.91, increasing by 72.73% over the last 12 months. The company has a consensus rating of "Moderate Buy" from analysts, with an average price target of $141.57. In Q3 2025, Rhythm Pharmaceuticals reported an EPS of -$0.82, missing estimates, but revenue of $51.30 million exceeded expectations. Preliminary Q4 2025 global net product revenues from IMCIVREE were approximately $57 million, an 11% increase from the previous quarter, and full-year 2025 revenue was about $194 million, a 50% increase from 2024. The company is awaiting an FDA decision for IMCIVREE in acquired hypothalamic obesity by March 2026, and positive Phase 2 trial data in Prader-Willi syndrome influenced analyst adjustments. There have been no insider buys, but 42 insider sells, including CFO Hunter Smith selling 6,628 shares in February 2026.

Demand for Rhythm Pharmaceuticals' products, primarily IMCIVREE, does not exhibit significant seasonality. Steady revenue growth indicates consistent demand driven by the medical need for treatments for rare genetic obesity disorders rather than seasonal fluctuations. Growth is tied to label expansions, international reimbursement wins, and new indications, suggesting a continuous demand pattern.

Rhythm Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing precision medicines for rare neuroendocrine diseases, particularly those involving the MC4R pathway. Their flagship product, IMCIVREE (setmelanotide), is approved for chronic weight management in patients with obesity due to specific genetic deficiencies and Bardet-Biedl syndrome. The company is also advancing a clinical development program for setmelanotide in other rare MC4R pathway diseases and has other investigational MC4R agonists in its pipeline.

Rhythm Pharmaceuticals is headquartered in Boston, Massachusetts, and commercializes IMCIVREE in North America, Europe, and other regions. U.S. sales account for a significant portion of its net product revenues, contributing 68% of the fourth quarter 2025 and 69% of the full-year 2025 figures.

Rhythm Pharmaceuticals maintains a positive brand reputation, driven by the performance of IMCIVREE. Analysts have a "Moderate Buy" consensus rating for the stock, with a positive outlook on future performance and revenue growth. The company's focus on rare neuroendocrine diseases and precision medicines is viewed favorably, and positive clinical trial data and revenue growth have contributed to a favorable perception.

Rhythm Pharmaceuticals has significant institutional ownership, with 500 institutional owners and shareholders holding 84,046,284 shares as of February 4, 2026. Major institutional shareholders include BlackRock, Inc., Vanguard Group Inc, Ra Capital Management, L.p., Baker Bros. Advisors Lp, Primecap Management Co/ca/, NEA Management Company, LLC, POAGX - PRIMECAP Odyssey Aggressive Growth Fund, Perceptive Advisors Llc, Fmr Llc, and Vanguard Total Stock Market Index Fund Investor Shares. Institutional ownership accounts for 99.02% of the company, while individuals hold 0.67%.